Stockscreener 앱 받기
3.8843
0.89%
-0.0357
전일 마감가:
$3.92
열려 있는:
$3.98
하루 거래량:
1.77M
Relative Volume:
0.32
시가총액:
$1.43B
수익:
$4.09M
순이익/손실:
$-660.15M
주가수익비율:
-1.6849
EPS:
-2.3053
순현금흐름:
$-117.10M
1주 성능:
+1.97%
1개월 성능:
-3.24%
6개월 성능:
-6.16%
1년 성능:
+84.12%
1일 변동 폭
$3.87
$4.0665
1주일 범위
$3.6701
$4.0665
52주 변동 폭
$2.00
$6.75
Ataibeckley Inc Stock (ATAI) Company Profile
명칭
Ataibeckley Inc
전화
1 929 207 2670
주소
C/O ATAI LIFE SCIENCES US, INC., NEW YORK
Compare ATAI vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATAI
Ataibeckley Inc
|
3.885 | 1.44B | 4.09M | -660.15M | -117.10M | -2.3053 |
VRTX
Vertex Pharmaceuticals Inc
|
451.93 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
613.22 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.82 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.93 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
159.78 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ataibeckley Inc Stock (ATAI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-27 | 개시 | Deutsche Bank | Buy |
| 2026-01-20 | 개시 | Guggenheim | Buy |
| 2025-10-13 | 개시 | Needham | Buy |
| 2025-07-29 | 개시 | Oppenheimer | Outperform |
| 2024-11-18 | 재확인 | H.C. Wainwright | Buy |
| 2024-04-03 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-11-01 | 개시 | Loop Capital | Buy |
| 2021-11-30 | 개시 | Maxim Group | Buy |
| 2021-11-11 | 개시 | ROTH Capital | Buy |
| 2021-10-18 | 개시 | H.C. Wainwright | Buy |
| 2021-09-01 | 개시 | Jefferies | Buy |
| 2021-07-13 | 개시 | Berenberg | Buy |
| 2021-07-13 | 개시 | Canaccord Genuity | Buy |
| 2021-07-13 | 개시 | Cantor Fitzgerald | Buy |
| 2021-07-13 | 개시 | Citigroup | Buy |
| 2021-07-13 | 개시 | Cowen | Outperform |
| 2021-07-13 | 개시 | Credit Suisse | Outperform |
| 2021-07-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-07-08 | 개시 | Aegis Capital | Buy |
모두보기
Ataibeckley Inc 주식(ATAI)의 최신 뉴스
ATAI: Advancing late-stage psychedelics for depression with key data readouts and strong financial runway - TradingView
ATAI: Advancing late-stage psychedelics for mental health, with key phase III and II-B trials underway - TradingView
Is AtaiBeckley Inc. (ATAI) the Hidden Penny Stock to Invest In? - Yahoo Finance
AtaiBeckley Inc. (ATAI) Holds Above Key Support, Posts Modest GainTrend Continuation Trade - newsline.com
ATAIBECKLEY INC. Files Form 8-K with SEC: Company Details, Stock Information, and NASDAQ Listing - Minichart
H.C. Wainwright reiterates Buy on Atai stock, $25 target By Investing.com - Investing.com Australia
AtaiBeckley Inc. (ATAI) awards 121,968 stock options to director - Stock Titan
AtaiBeckley Inc. (ATAI) director granted 121,968 stock options at $4.50 - Stock Titan
AtaiBeckley (ATAI) grants director 121,968 stock options at $4.50 - Stock Titan
AtaiBeckley (NASDAQ: ATAI) shareholders back board slate and Deloitte as 2026 auditor - Stock Titan
H.C. Wainwright reiterates Buy on Atai stock, $25 target - Investing.com UK
Atai Beckley N.V. (ATAI) A Top Penny Stock to Buy Poised to Build Sustained Clinical and Shareholder Value - Yahoo Finance
ATAI Q1 2026 Earnings: Narrower Loss Beats Estimates, Stock Declines Amid Market VolatilityEarnings Quality Score - newsline.com
AtaiBeckley (ATAI) Among the Best Penny Stocks with Huge Upside Potential - Insider Monkey
AtaiBeckley (ATAI) Drops Over 12%: Testing Key Support at $3.75Value Stock Ideas - newsline.com
5 Best Penny Stocks with Huge Upside Potential - Insider Monkey
Small cap wrap: Gunnison Copper, Trillion Energy, AtaiBeckley… - Proactive financial news
AtaiBeckley nears key clinical catalysts, Jefferies stays positive with repeat ‘Buy’ rating - Yahoo! Finance Canada
Is AtaiBeckley’s BPL-003 Phase 3 Launch Altering The Investment Case For AtaiBeckley (ATAI)? - Yahoo Finance
Jefferies reiterates atai Life Sciences stock rating on pipeline progress - Investing.com
Assessing AtaiBeckley (ATAI) Valuation After Strong Returns And Elevated Price To Book Ratio - Yahoo Finance
Is AtaiBeckley (ATAI) Using BPL-003’s Phase 3 Launch to Redefine Its Risk‑Reward Profile? - simplywall.st
ATAI: BPL-003 enters phase III for depression, with top-line data expected in early 2029 - TradingView
ATAI: BPL-003 phase III for depression begins, with VLS-01 phase IIb results due Q4 2024 - TradingView
AtaiBeckley to discuss Phase 3 BPL-003 program at multiple June investor conferences - TradingView
AtaiBeckley (NASDAQ: ATAI) to present BPL-003 Phase 3 updates - Stock Titan
ATAI Q1 2026 Earnings: Narrower Than Expected Loss Drives Positive Surprise Despite Modest Stock Decline - newsline.com
AtaiBeckley Grant Program Links Mental Health Impact With Investor Considerations - Sahm
ATAI Q1 2026 Earnings: Narrower Loss Beats Estimates; Stock Edges HigherEarnings Weakness Phase - thelegaladvocate.com
AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations - Investing News Network
Small cap wrap: AtaiBeckley, Medicus Pharma, Bit Digital, American Resources, Nextech3D.ai… - Proactive financial news
AtaiBeckley launches mental health patient impact grant program - Proactive financial news
New $20,000 mental health grants for nonprofits now open for applications - Stock Titan
AtaiBeckley to present at multiple investor conferences in June 2026, highlighting its mental health drug pipeline. - Pluang
AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026 - Investing News Network
AtaiBeckley to participate in multiple June investor conferences - Proactive financial news
AtaiBeckley Inc. Cash Flow – HAM:B72 - TradingView
Total debt of AtaiBeckley Inc. – HAM:B72 - TradingView
AtaiBeckley Inc. Balance Sheet – HAM:B72 - TradingView
Return on assets % of AtaiBeckley Inc. – HAM:B72 - TradingView
AtaiBeckley Inc. Trade Ideas — HAM:B72 - TradingView
ATAI Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesInterim Report - newsline.com
ATAI Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Pipeline AdvancesRevenue Beat Analysis - newsline.com
AtaiBeckley (ATAI) Reports Q1 Financial Results - Insider Monkey
AtaiBeckley Inc. (ATAI) Surges 5.87%: Testing Key Resistance LevelsDip Buy Trade - The Legal Advocate
10 Best Penny Stocks to Buy for Long Term - Insider Monkey
These stocks are today’s movers: Fermi, AST SpaceMobile, Intel, Marvell, USA Rare Earth, Ataibeckley, and more - MSN
AtaiBeckley Inc. (NASDAQ: ATAI): Advancing Psychedelic Mental Health Therapies with Clinical Momentum - Kalkine
How AtaiBeckley’s Wider Q1 Loss But Lower Per-Share Hit At AtaiBeckley (ATAI) Has Changed Its Investment Story - simplywall.st
Trump's psychedelic drug order boosts investor interest with promise of faster reviews - marketscreener.com
A Look At AtaiBeckley (ATAI) Valuation As Share Price Momentum And DCF Signal Differ - Yahoo Finance
Ataibeckley Inc (ATAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Ataibeckley Inc 주식 (ATAI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Craig Kevin James | Chief Medical Officer |
Apr 20 '26 |
Sale |
5.00 |
42,579 |
212,895 |
8,437 |
1.35%
0.76%
자본화:
|
볼륨(24시간):